Altogether 255 (1.4%) patients with canonical HRAS mutations were identified in the MSK-IMPACT and DFCI-Genie cohorts, with the number and relative frequency in the evaluated cancer types shown in Figure 1A, top panel. This evidence concerns the gene HRAS and cancer.